Kras G12c Mutation clinical trials

Explore recruiting kras g12c mutation clinical trials.

Recruiting kras g12c mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Kras G12c Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

Netherlands, Hungary, Germany, Belgium, France, Spain +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation

Portugal, Germany, Bulgaria, Ireland, Poland, Italy +13 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Hungary, Poland, Spain, France, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Germany, Romania, Hungary, Italy, Czechia, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)

Hungary, Romania, Netherlands, Austria, Croatia, France +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Kras G12c Mutation trials by city

Kras G12c Mutation in Toronto Kras G12c Mutation in Vancouver Kras G12c Mutation in Montreal Kras G12c Mutation in Calgary Kras G12c Mutation in Edmonton Kras G12c Mutation in Ottawa Kras G12c Mutation in Winnipeg Kras G12c Mutation in Quebec City Kras G12c Mutation in Hamilton Kras G12c Mutation in Kitchener Kras G12c Mutation in London Kras G12c Mutation in Halifax Kras G12c Mutation in New York Kras G12c Mutation in Los Angeles Kras G12c Mutation in Chicago Kras G12c Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease